Contact
searchSearch
HMP Global
Login
Quiz

Niraparib Plus Dostarlimab for Patients With Germline BRCA1/2-Mutated TNBC

12/11/2025

Related Content

News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
Marija Balic, MD, PhD
Conference Coverage
ctDNA Detection After Neoadjuvant Therapy Strongly Predicts Recurrence Risk in Early-Stage Triple-Negative Breast Cancer
12/18/2025
Marija Balic, MD, PhD
Marija Balic, MD, PhD, discusses results from the NSABP B-59/GBG-96-GeparDouze ctDNA sub-study evaluating whether molecular residual disease detected by ctDNA can predict recurrence risk after neoadjuvant therapy and surgery in early-stage...
Marija Balic, MD, PhD, discusses results from the NSABP B-59/GBG-96-GeparDouze ctDNA sub-study evaluating whether molecular residual disease detected by ctDNA can predict recurrence risk after neoadjuvant therapy and surgery in early-stage...
Marija Balic, MD, PhD, discusses...
12/18/2025
Oncology
Johannes Holtschmidt, MD
Conference Coverage
Prognostic Value of Ki67 and Tumor-Infiltrating Lymphocytes in Residual Tumor Following Neoadjuvant Chemotherapy for TNBC
12/10/2025
Johannes Holtschmidt, MD
Johannes Holtschmidt, MD, discusses results from a pooled analysis showing that Ki67 and tumor-infiltrating lymphocytes in residual tumor improve prognostic assessment for patients with triple-negative breast cancer who do not achieve...
Johannes Holtschmidt, MD, discusses results from a pooled analysis showing that Ki67 and tumor-infiltrating lymphocytes in residual tumor improve prognostic assessment for patients with triple-negative breast cancer who do not achieve...
Johannes Holtschmidt, MD,...
12/10/2025
Oncology
Conference Coverage
Niraparib Plus Dostarlimab Demonstrates Meaningful Neoadjuvant Activity in Germline BRCA1/2-Mutated TNBC
12/10/2025
Stephanie Holland
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the...
12/10/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use